Yanfeng is the Head of the Pharmacokinetics and Clinical Pharmacology group at Ionis, a leading biopharmaceutical company specializing in antisense oligonucleotides drug development. Prior to joining Ionis, Yanfeng worked for Novartis and Merck for nearly 20 years and led DMPK and Clinical Pharmacology teams supporting oncology and neuroscience therapeutic areas, as well as various rare disease indications. He is experienced in PK/PD (pharmacokinetic/pharmacodynamic) modeling, E/R (exposure/response) analysis, interspecies scaling, and evaluation of various intrinsic and extrinsic factors (eg, DDIs, polymorphisms of CYPs or transporters, IM/ADA, special populations, QT, etc) that may have an impact on safety and efficacy. He advocates for model-based drug development and therapeutic drug/biomarker monitoring for individualized therapies. Yanfeng made significant contributions to the development and approval of multiple novel therapeutic agents, including nilotinib, midostaurin, pasireotide, sonidegib, and ceritinib. More recently at Ionis, he contributed to the approval of nusinersen (2016), inotersen (2018), and volanesorsen (2019). Yanfeng received his Ph.D. in Pharmaceutical Sciences from the University of Minnesota. He has published over 80 papers in refereed journals. He is reviewer of multiple journals and a member of AAPS, ASCPT/ICoP, ASCO, and SAPA.
Tuesday, November 5
9:30 AM – 10:00 AM